The PDX ROS1-fusion tumor cell line, LUAD-0006, is resistant to all

IJMS, Free Full-Text

Protein tyrosine kinase inhibitor resistance in malignant tumors

A highly multiplexed quantitative phosphosite assay for biology

Inna Khodos's research works Memorial Sloan Kettering Cancer

Frontiers Ferroptosis-Related Genes in Lung Adenocarcinoma

Frontiers ROS1 Fusion Mediates Immunogenicity by Upregulation of

The PDX ROS1-fusion tumor cell line, LUAD-0006, is resistant to

PROTAC therapy as a new targeted therapy for lung cancer

Patient-derived xenograft culture-transplant system for investigation

Marissa Mattar's research works Memorial Sloan Kettering Cancer

Gregory J. Riely's research works

Frontiers ROS1 Fusion Mediates Immunogenicity by Upregulation of

Targeted therapy for rare lung cancers: Status, challenges, and